Efficacy and Safety of Low-intensity Shock Wave Therapy in Penile Rehabilitation Post Nerve-sparing Radical Cystoprostatectomy: a Randomized Controlled Trial
Overview
Authors
Affiliations
Aim: To evaluate the role of low-intensity extra corporeal shock wave therapy (LI-ESWT) in penile rehabilitation (PR) post nerve-sparing radical cystoprostatectomy (NS-RCP).
Materials And Methods: This study included 152 sexually active men with muscle invasive bladder cancer. After bilateral NS-RCP with orthotopic diversion by a single expert surgeon between June 2014 and July 2016, 128 patients were available categorized into three groups: LI-ESWT group (42 patients), phosphodiesterase type-5 inhibitors (PDE5i) group (43 patients), and control group (43 patients).
Results: Mean age was 53.2 ± 6.5 years. Mean ± SD follow-up period was 21 ± 8 months. During first follow-up FU1, all patients of the three groups had insufficient erection for vaginal penetration; with decrease of preoperative IIEF-EF mean score from 27.9 to 6.9. Potency recovery rates at 9 months were 76.2%, 79.1%, and 60.5% in LI-ESWT, PDE5i, and control groups, respectively. There was statistically significant increase in IIEF-EF and EHS scores during all follow-up periods in all the study groups (p < 0.001). However, there was no significant difference between the three groups during all follow-up periods. Statistical evaluation showed no significant difference in continence and oncological outcomes during all follow-up points among the three groups (p = 0.55 and 0.07, respectively).
Conclusions: During last follow-up, 16% more patients in LI-ESWT group had recovery of potency as compared to the control group. Although the difference is not statistically significant, but of clinical importance. LI-ESWT is safe as oral PDE5i in penile rehabilitation post nerve-sparing radical cystoprostatectomy.
He S, Zhang S, Sun X, Liu R, Yuan T, Chen X Heliyon. 2024; 10(13):e33834.
PMID: 39027554 PMC: 11255577. DOI: 10.1016/j.heliyon.2024.e33834.
Hinojosa-Gonzalez D, Talamas Mendoza A, Torres-Martinez M, Diaz-Garza K, Hernandez B, Munoz Hibert M Int J Impot Res. 2024; .
PMID: 38778153 DOI: 10.1038/s41443-024-00910-w.
Medrano-Sanchez E, Pena-Cantonero B, Candon-Ballester P, Blanco-Diaz M, Diaz-Mohedo E J Pers Med. 2024; 14(2).
PMID: 38392610 PMC: 10890328. DOI: 10.3390/jpm14020177.
Hayon S, Panken E, Bennett N World J Mens Health. 2023; 42(2):283-289.
PMID: 37853533 PMC: 10949028. DOI: 10.5534/wjmh.230105.
Matthew A, Rogers D, Grob G, Blottner M, Kodama S, Krzastek S Transl Androl Urol. 2023; 12(6):1023-1032.
PMID: 37426598 PMC: 10323450. DOI: 10.21037/tau-22-791.